BLPH logo

Bellerophon Therapeutics (BLPH) Cash From Operations

Annual CFO

-$17.77 M
+$5.05 M+22.13%

December 31, 2022

Summary

Performance

1-Year Change

+22.13%

3-Year Change

-37.37%

5-Year Change

-11.79%

15-Year Change

-11.79%

BLPH Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$12.94 M

3-Year Low

-$22.82 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2022
BLPH previous annual earnings announcement was published on Dec 31, 2022

Next Annual Earnings Report Date

N/A
BLPH next annual earnings announcement has not yet been scheduled

OtherBLPHcash flowmetrics:

Annual CFI

-
BLPH annual cash flow from investing activities value is unknown

Annual CFF

-$40.00 K
BLPH annual cash flow from financing activities is -$40.00 thousand

Annual FCF

-$17.77 M
BLPH annual free cash flow is -$17.77 million

Annual CAPEX

-
BLPH annual capital expenditures value is unknown

Quarterly CFO

-$6.33 M
-$1.41 M-28.67%

September 30, 2023

Summary

Performance

3-Month Change

0%

1-Year Change

-26.39%

3-Year Change

-26.39%

5-Year Change

-17.83%

BLPH Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$3.27 M
BLPH quarterly cash flow from operations is currently -293.88% below its historical high of $3.27 million

3-Year Low

-$6.33 M
BLPH quarterly cash flow from operations is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
BLPH previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
BLPH next earnings announcement has not yet been scheduled

OtherBLPHcash flowmetrics:

Quarterly CFI

$140.00 K
BLPH quarterly cash flow from investing activities is $140.00 thousand

Quarterly CFF

$0.00
BLPH quarterly cash flow from financing activities is $0.00

Quarterly FCF

-$6.33 M
BLPH quarterly free cash flow is -$6.33 million

Quarterly CAPEX

-
BLPH quarterly capital expenditures value is unknown

TTM CFO

-$12.34 M
-$1.32 M-12.00%

September 30, 2023

Summary

Performance

3-Month Change

0%

1-Year Change

+29.07%

3-Year Change

+29.07%

5-Year Change

+29.07%

BLPH TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$9.77 M

3-Year Low

-$22.82 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
BLPH previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
BLPH next earnings announcement has not yet been scheduled

OtherBLPHcash flowmetrics:

TTM CFI

$140.00 K
BLPH TTM cash flow from investing activities is $140.00 thousand

TTM CFF

$4.97 M
BLPH TTM cash flow from financing activities is $4.97 million

TTM FCF

-$12.34 M
BLPH TTM free cash flow is -$12.34 million

TTM CAPEX

-
BLPH TTM capital expenditures value is unknown

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

BLPH Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+22.1%-26.4%+29.1%
3 y3 years-37.4%-26.4%+29.1%
5 y5 years-11.8%-17.8%+29.1%

BLPH Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+28.4%-293.9%at low+26.3%+85.0%
5 y5-year+37.4%+28.4%-293.9%+24.5%+26.3%+104.6%
alltimeall time+37.4%+297.1%-293.9%+383.1%+26.3%+471.9%

Bellerophon Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2023
-
-$6.33 M(+28.7%)
-$12.34 M(+12.0%)
Jun 2023
-
-$4.92 M(-250.7%)
-$11.02 M(+12.8%)
Mar 2023
-
$3.27 M(-175.0%)
-$9.77 M(-45.0%)
Dec 2022
-$17.77 M(-22.1%)
-$4.35 M(-13.1%)
-$17.77 M(+2.1%)
Sep 2022
-
-$5.01 M(+36.4%)
-$17.40 M(-3.2%)
Jun 2022
-
-$3.67 M(-22.5%)
-$17.97 M(-8.6%)
Mar 2022
-
-$4.74 M(+19.1%)
-$19.67 M(-13.8%)
Dec 2021
-$22.82 M(+14.8%)
-$3.98 M(-28.8%)
-$22.82 M(-9.6%)
Sep 2021
-
-$5.59 M(+4.0%)
-$25.25 M(+2.7%)
Jun 2021
-
-$5.37 M(-31.9%)
-$24.58 M(+4.9%)
Mar 2021
-
-$7.89 M(+23.1%)
-$23.43 M(+17.9%)
Dec 2020
-$19.88 M(+53.7%)
-$6.40 M(+30.3%)
-$19.88 M(+21.4%)
Sep 2020
-
-$4.92 M(+16.3%)
-$16.37 M(+6.2%)
Jun 2020
-
-$4.23 M(-2.5%)
-$15.42 M(+3.3%)
Mar 2020
-
-$4.34 M(+49.8%)
-$14.93 M(+15.4%)
Dec 2019
-$12.94 M(-16.5%)
-$2.89 M(-26.9%)
-$12.94 M(-8.3%)
Sep 2019
-
-$3.96 M(+5.8%)
-$14.10 M(-9.1%)
Jun 2019
-
-$3.74 M(+59.9%)
-$15.52 M(-10.8%)
Mar 2019
-
-$2.34 M(-42.4%)
-$17.39 M(+12.2%)
Dec 2018
-$15.49 M
-$4.06 M(-24.5%)
-$15.49 M(-2.7%)
DateAnnualQuarterlyTTM
Sep 2018
-
-$5.37 M(-4.3%)
-$15.93 M(+15.6%)
Jun 2018
-
-$5.62 M(+1165.1%)
-$13.79 M(+8.7%)
Mar 2018
-
-$444.00 K(-90.1%)
-$12.68 M(-20.2%)
Dec 2017
-$15.90 M(-7.7%)
-$4.50 M(+39.3%)
-$15.90 M(+15.0%)
Sep 2017
-
-$3.23 M(-28.5%)
-$13.82 M(-0.7%)
Jun 2017
-
-$4.51 M(+23.4%)
-$13.91 M(-1.9%)
Mar 2017
-
-$3.66 M(+51.2%)
-$14.18 M(-17.6%)
Dec 2016
-$17.21 M(-62.8%)
-$2.42 M(-27.2%)
-$17.21 M(-46.4%)
Sep 2016
-
-$3.32 M(-30.4%)
-$32.09 M(-19.2%)
Jun 2016
-
-$4.78 M(-28.6%)
-$39.71 M(-10.1%)
Mar 2016
-
-$6.69 M(-61.3%)
-$44.17 M(-4.5%)
Dec 2015
-$46.26 M(-34.4%)
-$17.30 M(+58.0%)
-$46.26 M(+11.9%)
Sep 2015
-
-$10.95 M(+18.6%)
-$41.36 M(-8.5%)
Jun 2015
-
-$9.23 M(+5.0%)
-$45.19 M(-7.3%)
Mar 2015
-
-$8.79 M(-29.1%)
-$48.77 M(-30.9%)
Dec 2014
-$70.56 M(+23.3%)
-$12.39 M(-16.2%)
-$70.56 M(+21.3%)
Sep 2014
-
-$14.78 M(+15.5%)
-$58.17 M(+34.1%)
Jun 2014
-
-$12.80 M(-58.2%)
-$43.39 M(+41.8%)
Mar 2014
-
-$30.59 M
-$30.59 M
Dec 2013
-$57.23 M(+58.0%)
-
-
Dec 2012
-$36.22 M
-
-

FAQ

  • What is Bellerophon Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for Bellerophon Therapeutics?
  • What is Bellerophon Therapeutics annual CFO year-on-year change?
  • What is Bellerophon Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Bellerophon Therapeutics?
  • What is Bellerophon Therapeutics quarterly CFO year-on-year change?
  • What is Bellerophon Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for Bellerophon Therapeutics?
  • What is Bellerophon Therapeutics TTM CFO year-on-year change?

What is Bellerophon Therapeutics annual cash flow from operations?

The current annual CFO of BLPH is -$17.77 M

What is the all time high annual CFO for Bellerophon Therapeutics?

Bellerophon Therapeutics all-time high annual cash flow from operations is -$12.94 M

What is Bellerophon Therapeutics annual CFO year-on-year change?

Over the past year, BLPH annual cash flow from operations has changed by +$5.05 M (+22.13%)

What is Bellerophon Therapeutics quarterly cash flow from operations?

The current quarterly CFO of BLPH is -$6.33 M

What is the all time high quarterly CFO for Bellerophon Therapeutics?

Bellerophon Therapeutics all-time high quarterly cash flow from operations is $3.27 M

What is Bellerophon Therapeutics quarterly CFO year-on-year change?

Over the past year, BLPH quarterly cash flow from operations has changed by -$1.32 M (-26.39%)

What is Bellerophon Therapeutics TTM cash flow from operations?

The current TTM CFO of BLPH is -$12.34 M

What is the all time high TTM CFO for Bellerophon Therapeutics?

Bellerophon Therapeutics all-time high TTM cash flow from operations is -$9.77 M

What is Bellerophon Therapeutics TTM CFO year-on-year change?

Over the past year, BLPH TTM cash flow from operations has changed by +$5.06 M (+29.07%)